Tredje AP fonden lessened its stake in Boston Scientific Corporation (NYSE:BSX) by 9.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 138,496 shares of the medical equipment provider’s stock after selling 14,090 shares during the period. Tredje AP fonden’s holdings in Boston Scientific were worth $4,040,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BSX. NGAM Advisors L.P. lifted its stake in shares of Boston Scientific by 12.4% in the second quarter. NGAM Advisors L.P. now owns 49,840 shares of the medical equipment provider’s stock valued at $1,382,000 after buying an additional 5,513 shares during the period. Janney Montgomery Scott LLC raised its position in Boston Scientific by 1.8% in the second quarter. Janney Montgomery Scott LLC now owns 53,602 shares of the medical equipment provider’s stock worth $1,486,000 after purchasing an additional 929 shares in the last quarter. CIBC Asset Management Inc raised its position in Boston Scientific by 0.5% in the second quarter. CIBC Asset Management Inc now owns 129,853 shares of the medical equipment provider’s stock worth $3,600,000 after purchasing an additional 689 shares in the last quarter. IFP Advisors Inc raised its position in Boston Scientific by 30.4% in the second quarter. IFP Advisors Inc now owns 9,077 shares of the medical equipment provider’s stock worth $252,000 after purchasing an additional 2,114 shares in the last quarter. Finally, Retirement Systems of Alabama raised its position in Boston Scientific by 0.3% in the second quarter. Retirement Systems of Alabama now owns 1,404,418 shares of the medical equipment provider’s stock worth $38,930,000 after purchasing an additional 4,875 shares in the last quarter. Institutional investors and hedge funds own 90.57% of the company’s stock.
In other news, EVP Timothy A. Pratt sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $28.22, for a total transaction of $282,200.00. Following the sale, the executive vice president now directly owns 164,681 shares of the company’s stock, valued at $4,647,297.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Valley Gold Master Fund L. Sun purchased 408,006 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The shares were bought at an average cost of $0.45 per share, for a total transaction of $183,602.70. In the last ninety days, insiders have sold 414,698 shares of company stock valued at $12,013,153. Company insiders own 0.74% of the company’s stock.
Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.31. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The company’s revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the business posted $0.27 earnings per share. equities research analysts forecast that Boston Scientific Corporation will post 1.25 EPS for the current year.
Several research analysts recently issued reports on BSX shares. Canaccord Genuity dropped their price target on shares of Boston Scientific from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, November 29th. Jefferies Group reissued a “hold” rating on shares of Boston Scientific in a research report on Thursday, September 7th. BMO Capital Markets reissued a “buy” rating and issued a $30.00 price target on shares of Boston Scientific in a research report on Friday, October 13th. J P Morgan Chase & Co reissued a “buy” rating on shares of Boston Scientific in a research report on Wednesday, November 29th. Finally, Zacks Investment Research lowered shares of Boston Scientific from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Boston Scientific presently has a consensus rating of “Buy” and a consensus price target of $30.61.
WARNING: This article was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/12/04/tredje-ap-fonden-trims-position-in-boston-scientific-corporation-bsx.html.
Boston Scientific Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).
What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.